Drug Profile
Influenza vaccine - Jiangsu Jindike Biotechnology
Alternative Names: Quadrivalent influenza vaccine - Jiangsu Jindike BiotechnologyLatest Information Update: 30 Dec 2021
Price :
$50
*
At a glance
- Originator Jiangsu Jindike Biotechnology
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza virus infections
Most Recent Events
- 19 Sep 2021 Launched for Influenza virus infections (In adolescents, In children, Prevention, In adults) in China (IM), prior to September 2021
- 19 Sep 2021 Preregistration for Influenza virus infections (In adolescents, In children, Prevention, In adults) in China (IM), prior to September 2021
- 19 Sep 2021 Registered for Influenza virus infections (In adolescents, In children, Prevention, In adults) in China (IM), prior to September 2021